Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exendin-4 Beta-cell Imaging in T2D
NCT04733508Unknown
- Sponsor
- Radboud University Medical Center
- Start
- Nov 2019
- Primary completion
- Jun 2022
- Modality
- Small Molecules, Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Open-label trial of 111In-DTPA-exendin-4 and IRDye800CW-exendin-4 in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Radboud University Medical Center. Primary endpoints: Pancreatic exendin uptake 111In-DTPA exendin-4, Pancreatic exendin uptake 111In-DTPA exendin-4 (Autoradiography) and 5 more. Status: unknown.
02
Drugs
111In-DTPA-exendin-4IRDye800CW-exendin-4
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04733508.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04733508.